•  
    April 24-25, 2020 Los Angeles, CA Intercontinental Hotel May 15-16, 2020 Chicago, IL The JW Marriott Chicago October 23-24, 2020 New York, NY The Conrad Hotel
     

    Agenda At-a-Glance*

    * Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

    Women's Cancers Track

    Molecular Advances and Emerging Treatment Strategies in Ovarian and Endometrial Cancers

    HER2-Positive and Triple-Negative Breast Cancers: An Evolving Treatment Landscape

    Advances in Hormone Receptor Positive Breast Cancer and Hereditary Breast Cancer Syndromes

    Supportive Care Track

    Supportive and Palliative Care: Managing Symptoms and Toxicities to Improve Patient Outcomes

    Optimizing Outcomes for Survivors of Cancer

    Genitourinary Cancers Track

    Prostate Cancer: An Evolving Treatment Landscape

    Treatment Selection in Renal Cell and Urothelial Carcinoma: Integrating Novel Agents into Daily Practice

    Head, Neck and Lung Cancers Track

    Emerging Agents in the Multimodal Management of Head, Neck, and Thyroid Cancers

    NSCLC and SCLC: Molecular Testing and Emerging Treatment Options

    Melanoma Cancer Track

    Melanoma:
    Evidence-Based Treatment Approaches for Adjuvant, Advanced, and Metastatic Melanoma

    Sarcoma Track

    Best Practices and Expanding Treatment Options in Soft Tissue Sarcoma

    Gastrointestinal Cancer Track

    Novel Approaches for the Management of Esophageal, Gastric, and Pancreatic Cancers

    Hereditary Gastrointestinal Cancers: From Family History to Management with Combination Therapy

    Reducing Risk: Current Clinical Evidence on Lifestyle Management and Cheopreventative Agents in Gastrointestinal Cancer

    Colorectal Cancer: Molecular Markers and Evidence-Based Best Practices for Systemic Treatment

    Hematologic Malignancies Track

    Non-Hodgkin and Hodgkin Lymphoma: An Individualized Treatment Approach

    Myeloid Malignancies: Molecular Markers and Targeted Therapies

    Molecular Drivers of Myeloproliferative Neoplasms: Impact on Diagnosis, Assessment, and Management

    Multiple Myeloma: Current Evidence-Based Management

    Chronic Lymphocytic Leukemia: Evaluating the Rapidly Changing Treatment Landscape

    Cancer Associated Venous Thromboembolic Disease: Current Guidance and Clinical Data

    Course Goal and Overview

    The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and management of a wide range of cancers.

    This innovative, live two-day curriculum provides a comprehensive update on oncologic clinical practice, including current best practices and guidelines, emerging clinical evidence, and recent expert opinion. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the master clinicians of Dana-Farber Cancer Institute.

    Target Audience

    This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.
     

  • Acknowledgements

    Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity.

    Astellas AstraZeneca Bristol-Myers Squibb Eisai, Inc.


    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

    This program is supported by an independent medical education grant from Celgene Corporation.

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This website uses cookies to ensure you get the best experience on our website. For more information on the cookies we use, please reference our Privacy Policy.
×